Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PGx Study to Develop and Validate the Predictive Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy

This study has been completed.
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University Identifier:
First received: August 9, 2010
Last updated: May 30, 2013
Last verified: May 2013
To develop and validate the predictive warfarin dosing algorithm.

Heart Valve Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy in Korean Patients

Resource links provided by NLM:

Further study details as provided by Inje University:

Primary Outcome Measures:
  • To Develop and Validate the Predictive Warfarin Dosing Algorithm [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Blood samples were taken from patients for genotyping about 8ml

Enrollment: 405
Study Start Date: March 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:
This study aims to develop and validate the predictive warfarin dosing algorithm for personalized warfarin pharmacotherapy in Korean patients.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
the patients taking warfarin

Inclusion Criteria:

  • the patients taking warfarin

Exclusion Criteria:

  • noncompliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01178502

Korea, Republic of
Inje University
Busan, Korea, Republic of, 614-735
Sponsors and Collaborators
Inje University
  More Information

Responsible Party: Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University Identifier: NCT01178502     History of Changes
Other Study ID Numbers: 09-025 
Study First Received: August 9, 2010
Last Updated: May 30, 2013
Health Authority: Korea: Institutional Review Board

Additional relevant MeSH terms:
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Anticoagulants processed this record on December 09, 2016